MX383697B - Moduladores de moleculas peque?as de pantotenato cinasas - Google Patents
Moduladores de moleculas peque?as de pantotenato cinasasInfo
- Publication number
- MX383697B MX383697B MX2018015170A MX2018015170A MX383697B MX 383697 B MX383697 B MX 383697B MX 2018015170 A MX2018015170 A MX 2018015170A MX 2018015170 A MX2018015170 A MX 2018015170A MX 383697 B MX383697 B MX 383697B
- Authority
- MX
- Mexico
- Prior art keywords
- small molecule
- molecule modulators
- treatment
- intended
- pantothenate kinases
- Prior art date
Links
- 108010021592 Pantothenate kinase Proteins 0.000 title abstract 3
- 102100024122 Pantothenate kinase 1 Human genes 0.000 title abstract 3
- 150000003384 small molecules Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 102100024127 Pantothenate kinase 2, mitochondrial Human genes 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662354012P | 2016-06-23 | 2016-06-23 | |
| PCT/US2017/039037 WO2017223474A1 (en) | 2016-06-23 | 2017-06-23 | Small molecule modulators of pantothenate kinases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018015170A MX2018015170A (es) | 2019-07-04 |
| MX383697B true MX383697B (es) | 2025-03-14 |
Family
ID=60783428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018015170A MX383697B (es) | 2016-06-23 | 2017-06-23 | Moduladores de moleculas peque?as de pantotenato cinasas |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10899734B2 (enExample) |
| EP (1) | EP3474667A4 (enExample) |
| JP (1) | JP7078555B2 (enExample) |
| KR (1) | KR102459256B1 (enExample) |
| CN (1) | CN109561680B (enExample) |
| AU (1) | AU2017281907B2 (enExample) |
| DO (1) | DOP2018000293A (enExample) |
| IL (1) | IL263649B (enExample) |
| MX (1) | MX383697B (enExample) |
| SA (1) | SA518400696B1 (enExample) |
| SG (1) | SG11201811023UA (enExample) |
| WO (1) | WO2017223474A1 (enExample) |
| ZA (1) | ZA201808099B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10899734B2 (en) | 2016-06-23 | 2021-01-26 | St. Jude Children's Research Hospital, Inc. | Small molecule modulators of pantothenate kinases |
| US11891378B2 (en) * | 2017-12-27 | 2024-02-06 | St. Jude Children's Research Hospital, Inc. | Small molecule modulators of pantothenate kinases |
| US11547709B2 (en) | 2017-12-27 | 2023-01-10 | St. Jude Children's Research Hospital, Inc. | Methods of treating disorders associated with castor |
| CA3106470A1 (en) * | 2018-07-17 | 2020-01-23 | Nippon Chemiphar Co., Ltd. | T-type calcium channel blocker |
| US20220185796A1 (en) * | 2019-03-27 | 2022-06-16 | St. Jude Children's Research Hospital | Small molecule modulators of pank |
| JP2022081710A (ja) * | 2019-03-29 | 2022-06-01 | ユーティアイ リミテッド パートナーシップ | 関節リウマチを治療するためのｔ型カルシウムチャネル阻害剤の使用 |
| CA3135344A1 (en) * | 2019-03-29 | 2020-10-08 | Nippon Chemiphar Co., Ltd. | Use of t-type calcium channel blocker for treating pruritus |
| US11752149B2 (en) | 2019-12-02 | 2023-09-12 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
| EP4262814A4 (en) * | 2020-12-16 | 2025-02-26 | St. Jude Children's Research Hospital, Inc. | Methods of treating disorders associated with castor |
| CN119654314A (zh) * | 2022-08-08 | 2025-03-18 | 艾捷斯治疗公司 | 作为jak2抑制剂的杂环酰胺和脲化合物 |
| CN119745886A (zh) * | 2025-01-20 | 2025-04-04 | 中国药科大学 | 4-异丙苯基乙酰哌嗪在制备抗阿尔茨海默病药物中的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6894063B2 (en) * | 2000-09-14 | 2005-05-17 | Schering Corporation | Substituted urea neuropeptide Y Y5 Receptor antagonists |
| AU2001294547A1 (en) * | 2000-09-14 | 2002-03-26 | Schering Corporation | Substituted urea neuropeptide y y5 receptor antagonists |
| AU2003236500B9 (en) * | 2002-06-12 | 2009-07-02 | Chemocentryx, Inc. | 1-aryl-4-substituted piperazine derivatives for use as CCR1 antagonists for the treatment of inflammation and immune disorders |
| US20050256130A1 (en) | 2002-06-12 | 2005-11-17 | Chemocentryx, Inc. | Substituted piperazines |
| US7262194B2 (en) | 2002-07-26 | 2007-08-28 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| US7582635B2 (en) * | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
| AR044688A1 (es) * | 2003-06-12 | 2005-09-21 | Euro Celtique Sa | Agentes terapeuticos utiles para el tratamiento del dolor |
| US7759348B2 (en) | 2003-07-30 | 2010-07-20 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| WO2005011653A2 (en) * | 2003-07-30 | 2005-02-10 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| EP1758884A2 (en) | 2004-05-20 | 2007-03-07 | Elan Pharmaceuticals, Inc. | N-cyclic sulfonamido inhibitors of gamma secretase |
| US7754724B2 (en) | 2005-06-30 | 2010-07-13 | Dow Agrosciences Llc | N-substituted piperazines |
| US20080153811A1 (en) | 2006-11-07 | 2008-06-26 | Joseph Barbosa | Methods of Treating Cognitive Impairment and Dementia |
| AU2008269128B2 (en) | 2007-06-25 | 2012-08-02 | Amgen Inc. | Phthalazine compounds, compositions and methods of use |
| DE102007035333A1 (de) * | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| US20100041663A1 (en) * | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| AU2012280420B2 (en) | 2011-07-01 | 2017-01-05 | Remynd Nv | 1, 2, 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases |
| CN104583194A (zh) * | 2012-05-11 | 2015-04-29 | 艾伯维公司 | 作为nampt抑制剂的哒嗪和吡啶衍生物 |
| TW201444821A (zh) * | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代之哌啶化合物及其作為食慾素受體調節劑之用途 |
| CA2982811A1 (en) | 2015-04-17 | 2016-10-20 | Indiana University Research And Technology Corporation | Hepatitis b viral assembly effectors |
| US10899734B2 (en) | 2016-06-23 | 2021-01-26 | St. Jude Children's Research Hospital, Inc. | Small molecule modulators of pantothenate kinases |
-
2017
- 2017-06-23 US US16/307,473 patent/US10899734B2/en active Active
- 2017-06-23 KR KR1020197000671A patent/KR102459256B1/ko active Active
- 2017-06-23 WO PCT/US2017/039037 patent/WO2017223474A1/en not_active Ceased
- 2017-06-23 EP EP17816310.1A patent/EP3474667A4/en active Pending
- 2017-06-23 AU AU2017281907A patent/AU2017281907B2/en active Active
- 2017-06-23 CN CN201780043423.3A patent/CN109561680B/zh active Active
- 2017-06-23 MX MX2018015170A patent/MX383697B/es unknown
- 2017-06-23 JP JP2018566834A patent/JP7078555B2/ja active Active
- 2017-06-23 SG SG11201811023UA patent/SG11201811023UA/en unknown
-
2018
- 2018-11-29 ZA ZA2018/08099A patent/ZA201808099B/en unknown
- 2018-12-11 IL IL263649A patent/IL263649B/en unknown
- 2018-12-19 SA SA518400696A patent/SA518400696B1/ar unknown
- 2018-12-21 DO DO2018000293A patent/DOP2018000293A/es unknown
-
2020
- 2020-12-14 US US17/120,800 patent/US20210246113A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2018000293A (es) | 2019-04-15 |
| US20210246113A1 (en) | 2021-08-12 |
| SG11201811023UA (en) | 2019-01-30 |
| CN109561680A (zh) | 2019-04-02 |
| RU2019101613A (ru) | 2020-07-23 |
| IL263649B (en) | 2022-04-01 |
| CN109561680B (zh) | 2021-07-13 |
| EP3474667A1 (en) | 2019-05-01 |
| EP3474667A4 (en) | 2019-11-27 |
| MX2018015170A (es) | 2019-07-04 |
| AU2017281907A1 (en) | 2019-01-03 |
| KR102459256B1 (ko) | 2022-10-25 |
| KR20190022620A (ko) | 2019-03-06 |
| US20190300499A1 (en) | 2019-10-03 |
| JP2019518764A (ja) | 2019-07-04 |
| NZ749147A (en) | 2024-04-26 |
| AU2017281907B2 (en) | 2021-10-21 |
| BR112018076441A2 (pt) | 2019-04-09 |
| WO2017223474A1 (en) | 2017-12-28 |
| ZA201808099B (en) | 2019-07-31 |
| CA3025260A1 (en) | 2017-12-28 |
| US10899734B2 (en) | 2021-01-26 |
| RU2019101613A3 (enExample) | 2020-12-03 |
| IL263649A (en) | 2019-01-31 |
| JP7078555B2 (ja) | 2022-05-31 |
| SA518400696B1 (ar) | 2023-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX383697B (es) | Moduladores de moleculas peque?as de pantotenato cinasas | |
| MX2024004440A (es) | Moduladores de molécula pequeña de pantotenato-cinasas. | |
| CL2016001595A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6. | |
| PH12016500432A1 (en) | Inhibitors of erk and methods of use | |
| MY196413A (en) | Substituted Carbonucleoside Derivatives Useful as Anticancer Agents | |
| MX2016013826A (es) | Formulaciones de peroxido y metodos y aplicaciones para utilizarlas. | |
| EA201892147A1 (ru) | Бициклические соединения | |
| MX2017004896A (es) | Uso de hexadeca-8, 15-dienal como producto quimico aromatico. | |
| PH12015502615B1 (en) | Chemical compounds | |
| WO2016055761A3 (en) | Source-linked electronic programming guide | |
| JO3794B1 (ar) | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون | |
| PH12014502803A1 (en) | Camsylate salt | |
| MX2017000524A (es) | Compuestos novedosos de pirimidina sustituida. | |
| PH12019500467A1 (en) | Benzo-fused heterocyclic derivatives useful agonists of gpr120 | |
| WO2020198526A3 (en) | Small molecule modulators of pank | |
| MY176521A (en) | Pyrrole-substituted indolone derivative, preparation method therefor, composition comprising the same and use thereof | |
| IN2014DN09584A (enExample) | ||
| GB2546206A (en) | Synthesis of chirally enriched 2,4-distributed tetrahydropyran-4-OL and its derivatives | |
| MY201533A (en) | Palm-based wax composition | |
| MX2016010268A (es) | Pirimidinimidazolaminas como modulares de actividad de cinasa. | |
| MX2016011629A (es) | Derivados de pirrol biciclicos utiles como agonistas de gpr120. | |
| MX2016015959A (es) | Derivados de carbamato los cuales son tanto inhibidores de la enzima fosfodiesterasa 4 (pde4) como antagonistas del receptor muscarinico m3. | |
| HK1250020A1 (zh) | 用於吡咯连接的二价化合物的化学合成的方法及其组合物 | |
| MX386660B (es) | Una mezcla enriquecida con la estereoquimica r,r de 3',4'-di-o-acetil-cis-quelactona para el tratamiento de la diabetes mellitus. | |
| Atkinson | The chemistry of saké-brewing |